Severe neurological effects, such as memory loss, disorientation, and impairments in motor skills, can result from a deficiency
Similarly, section 1833(t)(8)(F) of the Act requires under the OPPS that in the case of a Part B rebatable drug (except for a drug that has no copayment applied under subparagraph (E) of such section or for which payment is packaged into the payment for a covered OPD service or group of services), in lieu of the calculation of the copayment amount that would otherwise apply under the OPPS, the provisions of section 1847A(i)(5) of the Act shall, as determined appropriate by the Secretary, apply in the same manner as the provisions of section 1847A(i)(5) of the Act apply under that section
For most healthy adults, it's clinically insignificant, but people with cardiovascular conditions should discuss topical minoxidil use with a physician
Other peptides, like GHRPs and AOD-9604, show promise but are often used off-label or experimentally
The standard research protocol is 300 mcg per day, subcutaneous, administered in a fasted state, typically in the morning before food or exercise
What is missing There is no published human pharmacokinetic study of subcutaneous AOD-9604, no published human topical or intranasal exposure data, no Phase 3 efficacy trial, no long-term safety data beyond 24 weeks, and no published human cartilage or joint outcome data